Posted by Michael Wonder on 09 Oct 2024
FDA approves use of up to three tubes of Biofrontera's Ameluz (aminolevulinic acid hydrochloride) 10% topical gel in one treatment
7 October 2024 - Supplemental new drug application supported by two Phase 1 safety studies.
Biofrontera today announced that the US FDA has approved the Company’s supplemental new drug application to increase the maximally approved dosage from one to three tubes of Ameluz per treatment.
